Chemokines: Inflammatory mediators of atherosclerosis

Archives of Physiology and Biochemistry

Volumn 112, Issue 4-5, 2006, Pages 229-238

  Liehn, Elisa A ^a   Zernecke, Alma ^a   Postea, Otilia ^a   Weber, Christian ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Atherosclerosis; Chemokines; Leukocytes; Receptors

Indexed keywords

ALPHA CHEMOKINE; CHEMOKINE; MIGRATION INHIBITION FACTOR; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE;

ARTERY DISEASE; ARTERY WALL; ARTICLE; ATHEROSCLEROSIS; BLOOD CELL; BLOOD VESSEL WALL; EXTRAVASATION; HEART INFARCTION; HUMAN; MONOCYTE; MORBIDITY; MORTALITY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; STROKE; T LYMPHOCYTE;

ATHEROSCLEROSIS; CHEMOKINES; CHEMOTAXIS, LEUKOCYTE; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; RECEPTORS, CHEMOKINE; SIGNAL TRANSDUCTION;

EID: 33845900465     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.1080/13813450601093583     Document Type: Article

References (95)

1. Abi-Younes S, Sauty A, Mach F, Sukhova GK, Libby P, Luster AD. 2000. The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Cir Res 86:131-8.
2. Addison CL, Daniel TO, Burdick MD, Liu H, Ehlert JE, Xue YY, Buechi L, Walz A, Richmond A, Strieter RM. 2000. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ERL-CXC chemokine-induced angiogenic activity. J Immunol 165:5269-77.
3. Aslanian AM, Charo IF. 2006. Targeted disruption of the scavenger receptor and chemokine CXCL16 accelerates atherosclerosis. Circulation 114:583-90.
4. Baggiolini M, Dewald B, Moser B. 1994. Interleukine-8 and related chemotactic cytokines CXC and CC chemokines. Adv Immunol 55:97.
5. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ. 1997. A new class of membrane-bound chemokine with a CX3C motif. Nature 385:640-4.
6. Boisvert WA, Santiago R, Curtiss LK, Terkeltraub RA. 1998. A leukocyte homologue of the IL-8 receptor CXCR2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest 101:353-63.
7. -/- mice reveales a role for chemokines in the initiation of atherosclerosis. Nature 3954:894-7.
8. Burger-Kentischer A, Goebel H, Seiler R, Fraedrich G, Schafer HE, Dimmeler S, Kleemann R, Bernhagen J, Ihling C. 2002. Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation 105:1561-6.
9. Burger-Kentischer A, Gobel H, Kleemann R, Zernecke A, Bucala R, Leng L, Finkelmeier D, Geiger G, Schaefer HE, Schober A, Weber C, Brunner H, Rutten H, Ihling C, Bernhagen J. 2006. Reduction of the aortic inflammatory response in spontaneous atherosclerosis by blockade of macrophage migration inhibitory factor (MIF). Atherosclerosis 184:28-38.
10. Charo IF, Ransohoff RM. 2006. The many roles of chemokines and chemokine receptors in Inflammation. N Engl J Med 354:610-21.
11. Chen Z, Sakuma M, Zago AC, Zhang X, Shi C, Leng L, Mizue Y, Bucala R, Simon DI. 2004. Evidence for a role of macrophage inhibitory factor in vascular disease. Arterioscler Thromb Vasc Biol 4:709-14.
12. Chuntharapai A, Lee J, Herbert CA, Kim KJ. 1994. Monoclonal antibodies detect different distribution patterns of IL-8 receptor A and IL-8 receptor B on human peripheral blood leukocytes. J Immunol 153:5682-8.
13. Cinamon G, Shinder V, Alon R. 2001. Shear forces promote lymphocyte migration across vascular endothelium bearing apical chemokines. Nat Immunol 2:515-22.
14. Clemetson KJ, Clemetson JM, Proudfoot AE, Power CA, Baggioloni M, Wells TN. 2000. Functional expression of CCR1, CCR3, CCR4 and CXCR4 chemokine receptors on human platelets. Blood 96:4046-56.
15. Combadiere C, Potteaux S, Gao JL, Esposito B, Casanova S, Lee EJ, Debre P, Tedgui A, Murphy PM, Mallat Z. 2003. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 107:1009-16.
16. Damas JK, Waehre T, Yndestadt A, Ueland T, Muller F, Eiken HG, Holm AM, Halvorsen B, Froland SS, Gullestad L, Aukrust P. 2002. Stromal cell-derived factor-1α in unstable angina: potential anti-inflammatory and matrix-stabilizing effects. Circulation 106:36-42.
17. Dawson TC, Kuziel WA, Osahar TA, Maeda N. 1999. Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 143:205-11.
18. Egashira K, Zhao Q, Kataoka C, Ohtani K, Usui M, Charo IF, Nishida K, Inoue S, Katoh M, Ichiki T, Takeshita A. 2002. Importance of monocyte chemoattractant protein-1 pathway in neointimal hyperplasia after periarterial injury in mice and monkeys. Circ Res 90:1167-72.
19. Erl W, Weber PC, Weber C. 1998. Monocytic cell adhesion to endothelial cells stimulated by oxidized low density lipoprotein is mediated by distinct endothelial ligands. Atherosclerosis 136(2):297-303.
20. Fong AM, Robinson LA, Steeber DA, Tedder TF, Yoshie O, Imai T, Patel DD. 1998. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion and activation under physiologic flow. J Exp Med 188:1413-9.
21. Furukawa Y, Matsumori A, Ohashi N, Shioi T, Ono K, Harada A, Matsushima K, Sasayama S. 1999. Anti-monocyte chemoattractant protein-1/monocyte chemotactic and activating factor antibody inhibits neointimal hyperplasia in injured rat carotid arteries. Circ Res 84:306-14.
22. Garton KJ, Gough PJ, Blobel CP, Murphy G, Greaves DR, Dempsey PJ, Raines EW. 2001. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 276:27993-38001.
23. George JN, Onofre AR. 1982. Human platelet surface binding of endogenous secreted factor VIII-von Willebrand factor and platelet factor 4. Blood 59:194-7.
24. Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA Jr, Luster AD, Luscinskas FW, Rosenzweig A. 1999. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 398:718-23.
25. Greaves DR, Häkkinen T, Lucas AD, Liddiard FR, Tyson K, Boyle J, Shanahan C, Weissberg PL, Gordon S, Ylä-Hertualla S. 2001. Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine and tymus- and activation-regulated chemokine, are expressed in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 21:923-9.
26. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ. 1998. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 2:275-81.
27. Haley KJ, Lilly CM, Yang JH, Feng Y, Kennedy SP, Turi TG, Thompson JF, Sukhova GH, Libby P, Lee RT. 2000. Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technologie to identify a potential novel path way of vascular inflammation. Circulation 102:2185-9.
28. Han KH, Tangirala RK, Green SR, Quehenberger O. 1998. Chemokine receptor CCR2 expression and monocyte chemoattractant protein-1-mediated chemotaxis in human monocytes. A regulatory role for plasma LDL. Arterioscler Thromb Vasc Biol 18:1983-91.
29. Hansson GK, Libby P, Schonbeck U, Yan ZQ. 2002. Innate and adaptative immunity in the pathogenesis of atherosclerosis. Circ Res 91:281-91.
30. Hansson GK, Libby P. 2006. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6:508-19.
31. Heller EA, Liu E, Tager AM, Yuan Q, Lin AY, Ahluwalia N, Jones K, Koehn SL, Lok VM, Aikawa E, Moore KJ, Luster AD, Gerszten RE. 2006. Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. Circulation 113:2301-12.
32. Horvath C, Welt FG, Nedelman M, Rao P, Rogers C. 2002. Targeting CCR2 or CD18 inhibits experimental in-stent restenosis in primates: inhibitory potential depends on type of injury and leukocytes targeted. Circ Res 90:488-94.
33. Huo Y, Weber C, Forlow SB, Sperandio M, Thatte J, Mack M, Jung S, Littman DR, Ley K. 2001. The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium. J Clin Invest 108:1307-14.
34. Huo Y, Schober A, Forlow B, Smith DF, Hyman MC, Jung S, Littman DR, Weber C, Ley K. 2003. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 9:61-7.
35. Koch AE, Polverini OJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG, Strieter RM. 1992. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258:1778-81.
36. Kowalska MA, Ratajczak MZ, Majka M, Jin J, Kunapuli S, Brass L, Poncz M. 2000. Stromal cell-derived factor-1 and macrophage-derived chemokine: 2 chemokines that activate platelets. Blood 96:50-7.
37. Kushert GS, Coulin F, Power CA, Proudfoot AE, Hubbard RE, Hoogewerf AJ, Wells TN. 1999. Glycozaminoglycans interact selectively with chemokines and modulate hreceptor binding and cellular responces. Biochemistry 38:12959-68.
38. Kuziel WA, Dawson TC, Quinones M, Garavito E, Chenaux G, Ahuja SS, Reddick RI, Maeda N. 2003. CCR5 deficiency is not protective in the early stages of atherogenesis in apoE knockout mice. Atherosclerosis 167:25-32.
39. Lapidot T, Petit I. 2002. Current understanding of stem cell mobilization: the role of chemokines, proteolytic enzymes, adhesion molecules, cytokines and stromal cells. Exp Hematol 30:973-81.
40. -/- mice reveals a role for fractalkine in atherogenesis. J Clin Invest 111:333-40.
41. Liehn EA, Schober A, Weber C. 2004. Blockade of keratinocyte-derived chemokine inhibits endothelial recovery and enhances plaque formation after arterial injury in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 24:1891-6.
42. Lin SG, Yu XY, Chen YX, Huang XR, Mets C, Bucala R, Lau CP, Lau HY. 2000. De novo expression of macrophage migration inhibitory factor in atherogenesis in rabbits. Circ Res 87:1202-8.
43. Ludwig A, Berkhout T, Moores K, Groot P, Chapman G. 2002. Fractalkine is expressed by smooth muscle cells in response to IFN-gamma and TNF-alpha and is modulated by metalloproteinase activity. J Immunol 168:604-12.
44. Lundahl J, Skols CM, Hallden G, Hallgren M, Eklund A. 1996. Monocytes and neutrophil adhesion to matrix proteins is selectively enhanced in the presence of inflammatory mediators. Scand J Immunol 44:143-9.
45. Mach F, Sauty A, Iarossi AS, Sukhova GK, Neote K, Libby P, Luster AD. 1999. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest 104:1041-50.
46. Matloubian M, David A, Engel S, Ryan JE, Cyster JG. 2000. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat Immunol 1:298-304.
47. Mause SF, von Hundelshausen P, Zernecke A, Koenen RR, Weber C. 2005. Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscler Thromb Vasc Biol 25:1512-8.
48. Minami M, Kume N, Shimaoka T, Kataoka H, Hayashida K, Akiyama Y, Nagata I, Ando K, Nobuyoshi M, Hanyuu M, Komeda M, Yonehara S, Kita T. 2001. Expression of SR-PSOX, a novel cell-surface scavenger receptor for phosphatidylserine and oxidized LDL in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 21:1796-800.
49. Morand EF, Leech M, Bernhagen J. 2006. MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov 5:399-410.
50. Moser B, Barella L, Mattei S, Schumacher C, Boulay F, Colombo MP, Baggiolini M. 1993. Expression of transcripts for two interleukin 8 receptors in human phagocytes, lymphocytes and melanoma cells. Biochem J 294:285-92.
51. Namiki M, Kawashima S, Yamashita T, Ozaki M, Hirase T, Ishida T, Inoue N, Hirata K, Matsukawa A, Morishita R, Kaneda Y, Yokoyama M. 2002. Local overexpression of monocyte chemoattractant protein-1 at vessel wall induces infiltration of macrophages and formation of atherosclerotic lesion: synergism with hypercholesterolemia. Arterioscler Thromb Vasc Biol 22:115-20.
52. Neuzil J, Schroder A, von Hundelshausen P, Zernecke A, Weber T, Gellert N, Weber C. 2001. Inhibition of inflammatory endothelial responses by a pathway involving caspase activation and p65 cleavage. Biochemistry 40(15):4686-92.
53. Ni W, Egashira K, Kitamoto S, Kataoka C, Koyanagi M, Inoue S, Imaizumi K, Akiyama C, Nishida KI, Takeshita A. 2001. New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice. Circulation 103:2096-101.
54. Pan JH, Sukhova GK, Yang JT, Wang B, Xie T, Fu H, Zhang Y, Satoskar AR, David JR, Metz CN, Bucala R, Fang K, Simon DI, Chapman HA, Libby P, Shi GP. 2004. Macrophage migration inhibitora factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 109:3149-4153.
55. Piali L, Weber C, LaRosa G, Mackay CR, Springer TA, Clark-Lewis J, Moser B. 1998. The chemokine receptor CXCR3 mediates rapid and shear-resistant adhesion-induction of effector T Lymphocytes by chemokines IP10 and Mig. Eur J Immunol 28:961-72.
56. Reape TJ, Groot PH. 1999. Chemokines and atherosclerosis. Atherosclerosis 147:213-25.
57. Rollins BJ. 1997. Chemokines. Blood 90(3):909-28.
58. Roque M, Kim WJ, Gazdoin M, Malik A, Reis ED, Fallon JT, Badimo JJ, Charo IF, Taubman MB. 2002. CCR2 deficiency decreases intimal hyperplasia after arterial injury. Arterioscler Thromb Vasc Biol 22:554-9.
59. Sata M, Saiura A, Kunisato A, Tojo A, Okada S, Tokuhisa T, Hirai H, Makuuchi M, Hirata Y, Nagai R. 2002. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 8:403-9.
60. Schäfer A, Schultz C, Eigenthaler M, Fraccarolo D, Kobsar A, Gawaz M, Ertl G, Walter U, Bauersachs J. 2003. Novel role of the chemokine fractalkine in platelet activation and adhesion. Blood 103:407-12.
61. Schober A, Manka D, von Hundelshausen P, Huo Y, Hanrath P, Sarembock IJ, Ley K, Weber C. 2002. Deposition of platelet RANTES triggering monocytes recruitment requires P-Selectin and is involved in neointima formation after arterial injury. Circulation 106:1523-9.
62. Schober A, Knarren S, Lietz M, Lin EA, Weber C. 2003. Crucial role of stromal cell-derived factor-1α in neointima formation after vascular injury in apolipoprotein E-deficient mice. Circulation 108:2491-7.
63. Schober A, Bernhagen J, Thiele M, Zeiffer U, Knarren S, Roller M, Bucala R, Weber C. 2004. Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. Circulation 109:380-5.
64. Schober A, Zernecke A, Liehn EA, von Hundelshausen P, Knarren S, Kuziel WA, Weber C. 2004. Crucial role of the CCL2/CCR2 axis in neointimal hyperplasia after arterial injury in hyperlipidemic mice involves early monocyte recruitment and CCL2 presentation on platelets. Circ Res 95:1125-33.
65. Schober A, Karshovska E, Zernecke A, Weber C. 2006. SDF-1α-mediated tissue repair by stem cells: a promising tool in cardiovascular medicine? Trends Cardiovasc Med 16:103-8.
66. Schwarz D, Andalibi A, Chaverri-Almada L, Berliner JA, Kirchgessner T, Fang ZT, Tekamp-Olson P, Lusis AJ, Gallegos C, Fogelman AM, et al. 1994. Role of GRO family of chemokines in monocyte adhesion to MM-LDL-stimulated endothelium. J Clin Invest 94:1968-73.
67. Springer TA. 1994. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76:301-14.
68. Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y, Kitamura Y, Matsusima K, Yoshida N, Nischikawa S, Kishimoto T, Nagasawa T. 1998. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 393:591-4.
69. Taubman MB, Rollins BJ, Poon M, Marmur J, Green RS, Berk BC, Nadal-Ginard B. 1992. JE mRNA accumulates rapidly in aortic injury and in platelets-derived growth factor-stimulated vascular smooth muscle cells. Circ Res 70:314-25.
70. Tegui A, Mallat Z. 2006. Cytokines and atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 86:515-81.
71. -/- mice. Proc Natl Acad Sci U S A 103:123-8.
72. Trogan E, Feig JE, Dogan S, Rothblat GH, Angeli V, Tacke F, Randolph GJ, Fisher EA. 2006. Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc Natl Acad Sci U S A 103(10):3781-6.
73. Tsou CL, Haskell CA, Charo IF. 2001. Tumor necrosis factor-alpha- converting enzyme mediates the inducible cleavage of fractalkine. J Biol Chem 276:44622-6.
74. van Wanrooij EJ, Happe H, Hauer AD, de Vos P, Imanishi T, Fujiwara H, van Berkel TJ, Kuiper J. 2005. HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 25:2642-7.
75. Veillard NR, Kwak B, Pelli G, Mulhaupt F, James RW, Proudfoot AE, Mach F. 2004. Antagonism of RANTES receptors reduced atherosclerotic plaque formation in mice. Circ Res 94:253-61.
76. Veillard NR, Steffens S, Pelli G, Lu B, Kwak BR, Gerard C, Charo IF, Mach F. 2005. Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo. Circulation 112:870-8.
77. von Hundelshausen P, Weber KSC, Huo Y, Proudfoot AEI, Nelson PJ, Ley K, Weber C. 2001. RANTES deposition by platelets treggersmonocyte arrest on inflamed and atherosclerotic endothelium. Circulation 103:1772-7.
78. von Hundelshausen P, Koenen RR, Sack M, Mause SF, Adriaens W, Proudfoot AE, Hackeng TM, Weber C. 2005. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood 105:924-30.
79. Wang N, Tabas I, Winchester R, Ravalli S, Rabbani LE, Tall A. 1996. Interleukin-8 is induced by cholesterol loading of macrophages and expressed by macrophage foam cells in human atheroma. J Biol Chem 271:8837-42.
80. Weber KS, Klickstein LB, Weber C. 1999. Specific activation of leukocyte beta2 integrins lymphocyte function-associated antigen-1 and Mac-1 by chemokines mediated by distinct pathways via the alpha subunit cytoplasmic domains. Mol Biol Cell 10:861-73.
81. Weber KSC, von Hundelshausen P, Weber PC, Clark-Lewis I, Weber C. 1999. Differencial chemokine immobilization and hierarchical involvement of their receptors in monocyte arrest and transmigration on inflammatory endothelium. Eur J Immunol 29:700-12.
82. Weber C, Belge KU, von Hundelshausen P, Draude G, Steppich B, Mack M, Frankenberger M, Weber KS, Ziegler-Heitbrock HW. 2000. Differential chemokine receptor expression and function in human monocyte subpopulations. J Leukoc Biol 67:699-704.
83. Weber C, Weber KSC, Klier C, Gu H, Horuk R, Wank R, Nelson PJ. 2001. Specialized roles of the chemokines receptors CCR1 and CCR5 in recruitment of monocytes and Th1-like/CD45RO+T cells. Blood 97:1144-6.
84. Weber C. 2003. Novel mechanistic concepts for the control of leukocyte transmigration; specialization of integrins, chemokines and junctional molecules. J Mol Med 81:4-19.
85. Weber C, Schober A, Zernecke A. 2004. Chemokines: key regulators of mononuclear cells recruitment in atherosclerotic vascular disease. Arterioscler Thromb Vasc Biol 24:1997-2008.
86. Weber C. 2005a. Platelets and chemokines in atherosclerosis: partners in crime. Circ Res 96:612-6.
87. Weber C. 2005b. Killing two birds with one stone: targeting chemokine receptors in atherosclerosis and HIV infection. Arterioscler Thromb Vasc Biol 25:2448-50.
88. Weber C, Koenen RR. 2006. Fine-tuning leukocyte responses: towards a chemokine 'interactome'. Trends Immunol 27:268-73.
89. Wilcox JN, Nelken NA, Coughlin SR, Gordon D, Schall TJ. 1994. Local expression of inflammatory cytokines in human atherosclerotic plaque. J Atheroscler Thromb 1:S10-13.
90. Wuttge DM, Zhou X, Sheikine Y, Wagsater D, Stemme V, Hedin U, Stemme S, Hansson GK, Sirsjo A. 2004. CXCL16/SR-PSOX is an interferon-gamma-regulated chemokine and scavenger receptor expressed in atherosclerotic lesions. Arterioscler Thromb Vasc Biol 24:750-5.
91. Yu X, Dluz S, Graves DT, Zhang L, Antoniades HN, Hollander W, Prusty S, Valente AJ, Schwarz CJ, Sonenshein GE. 1992. Elevated expression of monocyte chemoattractant protein 1 by vascular smooth muscle cells in hypercholesterolemic primates. Proc Natl Acid Sci USA 89:6953-7.
92. Zernecke A, Weber KS, Erwig LP, Kluth DC, Schroppel B, Rees AJ, Weber C. 2001. Combinatorial model of chemokine involvement in glomerular monocyte recruitment: role of CXC chemokine receptor 2 in infiltration during nephrotoxic nephritis. J Immunol 166:5755-62.
93. Zernecke A, Schober A, Bot I, von Hundelshausen P, Liehn EA, Mopps B, Mericskay M, Gierschik P, Biessen EA, Weber C. 2005. SDF-1α/CXCR4 axis Is Instrumental in murine neointimal hyperplasia and recruitment of smooth muscle progenitor cells. Circ Res 96:784-91.
94. Zernecke A, Weber C. 2005. Inflammatory mediators in atherosclerotic vascular disease. Basic Res Cardiol 100:93-101.
95. Zernecke A, Liehn EA, Gao JL, Kuziel WA, Murphy PM, Weber C. 2006. Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: involvement of IL-10. Blood 107:4240-3.